EUCTR2009-009517-18-IT进行中（未招募）不适用
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study theSafety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 335
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All laboratory measurements are to be performed after an overnight fast ≥12 hours in
- •duration. Patients with laboratory screening values/findings not meeting protocol
- •inclusion criteria may, at the discretion of the investigator, have a single repeat
- •determination performed. If the repeat value satisfies the criterion, they may continue in
- •the screening process. Only the laboratory test(s) not meeting inclusion criteria should be
- •repeated (not the entire panel).
- •Patients must meet all of the following inclusion criteria to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •All laboratory measurements are to be performed after an overnight fast ≥12 hours in
- •duration. Patients with screening values outside the ranges described in the protocol
- •may, at the discretion of the investigator, have one repeat value determination performed
- •and if the repeat value does not meet the exclusion criterion they may continue the
- •screening process. Only the specific out-of-range value/finding should be repeated (not
- •the entire panel).
- •Individuals are excluded from participation in the study if they meet any of the following
- •exclusion criteria.
研究者
相似试验
Unknown
2 期
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlCTRI/2009/091/000614Merck Co Inc276
进行中（未招募）
1 期
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - A Study of the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus.MedDRA version: 9.1 Level: LLT Classification code 10012601 Term: Diabetes mellitusType 2 Diabetes MellitusEUCTR2009-009517-18-GRMerck & co.Inc333
进行中（未招募）
不适用
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled,Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients withType 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - A Study of the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus.MedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusType 2 Diabetes MellitusEUCTR2009-009517-18-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.333
已完成
不适用
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlPER-019-09MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled,Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients withType 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - A Study of the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus.Type 2 Diabetes MellitusEUCTR2009-009517-18-HUMerck and Co. Inc.241